Same day, different holiday: Mid-autumn festivals across East Asia
Yoon hosts luncheon meeting with Korean atomic bomb victims in Hiroshima on Chuseok
Swimmer, gamers celebrate Chuseok with gold medals
With teammate's help, inconsolable shooter regroups in time to win bronze
The many regional flavors of songpyeon, a Korean holiday dessert
Opposition leader proposes meeting with Yoon amid growing party feud
Whisky imports surge 40% through August, suggesting record-breaking year
NewJeans hits 1 bln streams mark on Spotify with debut album
Traffic heavy on expressways following Chuseok
Diplomatic vehicle blessed for safety via Hindu ritual by S. Korean Embassy in India
S. Korean drug firms rush to develop vaccines effective against omicronBy Yonhap
Published : Dec. 18, 2021 - 11:15
As the omicron variant fuels fears around the world that the pandemic could rage during the winter season, local pharmaceutical firms have either begun developing omicron-tailored vaccines or studying whether their vaccine candidates are effective against the strain.
The country does not have a homegrown COVID-19 vaccine yet, but amid the fast spread of the omicron variant, more Korean drugmakers are ramping up efforts to develop COVID-19 vaccines.
On Friday, the country added 7,435 more COVID-19 cases, raising the total caseload to 551,551, according to health authorities. Three more omicron variant cases were reported, putting the total at 151.
Leading drugmaker SK Bioscience said it has begun studying whether its COVID-19 vaccine candidate GBP510 is effective in fighting the omicron variant.
GBP510, under the development by a unit of the country's No. 2 family-controlled conglomerate SK Group, is the country's first homegrown vaccine candidate to enter the third and last phase of its clinical trial.
SK Bioscience said it has checked whether GBP510 created neutralizing antibodies against the omicron variant during animal testing. The results have not yet been released.
The clinical trial is comparing GBP510 against the COVID-19 vaccine by AstraZeneca and Oxford University to view immunogenicity and safety.
SK Bioscience earlier said it aims to produce an interim result of its final stage of the clinical trial in the first quarter of next year before seeking final approval. Commercialization is expected as early as in the first half of next year.
Smaller bio firm Genexine is also testing the effectiveness of its DNA-based vaccine candidate, GX-19N, against the omicron variant. The vaccine candidate is currently in phase two of its clinical trial.
Another smaller player, Eubiologics, meanwhile, has begun developing a omicron-targeted COVID-19 vaccine.
The company said it plans to conduct animal testing of its vaccine candidate within this month based on its own unique platform technology.
Small biotech firm Cellid also said it has begun the process of developing vaccines tailored to fight against the omicron variant. It will seek to get approval for a phase one clinical trial within the next three months.
The company's other viral vector vaccine against the COVID-19 virus is currently in the second phase of a clinical trial. (Yonhap)
S. Korea wins bronze in pistol mixed team event for 14th shooting medal
Heavy traffic on expressways expected on 4th day of holiday
Police launch belated probe into another teacher's suicide after parental harassment